Living with Hypertension: A Daily Management Guide

Being diagnosed with high blood pressure (hypertension) can feel overwhelming, but it is one of the most manageable chronic conditions. By combining the right daily habits, dietary adjustments, and consistent medication use, you can protect your heart and live a full, active life.

Whether you are dealing with the wear-and-tear of osteoarthritis or the autoimmune inflammation of rheumatoid arthritis, joint pain requires a proactive management strategy. In this guide, we cover daily pain relief techniques, the importance of low-impact movement, and how to navigate modern arthritis medications.

Receiving an Atrial Fibrillation (AFib) diagnosis can feel overwhelming, but it is a highly manageable condition. In this comprehensive guide, we explore how to identify your daily triggers, reduce your stroke risk, and effectively manage your heart health through diet, exercise, and targeted medications.

Living with Inflammatory Bowel Disease (IBD) requires a careful balance of diet, stress management, and targeted medical therapy. In this guide, we break down how to manage unexpected flare-ups, the importance of identifying your food triggers, and how modern biologics are making long-term remission more accessible.

Managing asthma is all about staying one step ahead of your symptoms. In this patient guide, we break down how to identify hidden environmental triggers, the critical differences between rescue and maintenance medications, and how to build an effective daily action plan.

Biosimilars like Hyrimoz, Hadlima, and Yuflyma are highly similar, FDA-approved alternatives to Humira (adalimumab). They offer the exact same safety, clinical strength, and effectiveness as the original biologic, often at a significantly lower cost.

Inflectra (infliximab-dyyb) is an FDA-approved biosimilar to Remicade (infliximab). Both are intravenous TNF-blocker biologics designed to treat moderate-to-severe Crohn's disease and ulcerative colitis with identical clinical effectiveness and safety.

Wezlana (ustekinumab-auub) is an FDA-approved biosimilar that is interchangeable with Stelara (ustekinumab). Both target IL-12 and IL-23 cytokines to treat plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis with equal safety and effectiveness.

Truxima (rituximab-abbs) is an FDA-approved biosimilar to Rituxan (rituximab). Both are targeted anti-CD20 monoclonal antibodies administered via intravenous infusion to treat rheumatoid arthritis, non-Hodgkin's lymphoma, and chronic lymphocytic leukemia with matching clinical outcomes and safety.

Jubbonti (denosumab-bbdz) is an FDA-approved biosimilar designated as interchangeable with Prolia (denosumab). Both target the RANKL protein to stop bone breakdown, treat postmenopausal osteoporosis, and increase bone mass with identical clinical efficacy and safety.